AgeX Therapeutics Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
AgeX Therapeutics General Information
Description
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. The company's product pipeline includes two cell-based and two iTR-based product candidates in development. Its lead cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1. Its lead small molecule drug-based therapeutic candidate for iTRTM in discovery is AGEX-iTR1547.
Contact Information
Website
www.agexinc.comCorporate Office
- 1010 Atlantic Avenue
- Suite 102
- Alameda, CA 94501
- United States
Corporate Office
- 1010 Atlantic Avenue
- Suite 102
- Alameda, CA 94501
- United States
AgeX Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 26-Mar-2024 | Completed | Generating Revenue | |||
| 5. IPO | 29-Nov-2018 | Completed | Generating Revenue/Not Profitable | |||
| 4. Merger/Acquisition | 08-Nov-2018 | Completed | Startup | |||
| 3. Grant | 02-May-2018 | Completed | Startup | |||
| 2. Grant | 15-Apr-2018 | $11.1M | $10.8M | Completed | Startup | |
| 1. Early Stage VC | 02-Aug-2017 | $10.8M | $10.8M | Completed | Startup |
AgeX Therapeutics Comparisons
Industry
Financing
Details
AgeX Therapeutics Competitors (55)
One of AgeX Therapeutics’s 55 competitors is Surrozen, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Surrozen | Formerly VC-backed | South San Francisco, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Ember Therapeutics | Formerly VC-backed | New York, NY |
AgeX Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AgeX Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AgeX Therapeutics Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| IBS Capital | Hedge Fund | Minority | ||
| James Mellon | Angel (individual) | Minority | ||
| Juvenescence | VC-Backed Company | Majority | ||
| Kizoo Technology Capital | Venture Capital | Minority | ||
| National institutes of Neurological Disorders and Stroke | Government |
AgeX Therapeutics Investments & Acquisitions (3)
AgeX Therapeutics’s most recent deal was a Reverse Merger with Serina Therapeutics for . The deal was made on 26-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Serina Therapeutics | 26-Mar-2024 | Reverse Merger | Drug Discovery | ||
| LifeMap Sciences | 15-Mar-2021 | Merger/Acquisition | Biotechnology | ||
| Escape Therapeutics (UniverCyte Technology Patent in Silicon Valley, California) | 16-Aug-2019 | Corporate Asset Purchase | Buildings and Property |
AgeX Therapeutics Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| LifeMap Sciences | Biotechnology | Covina, CA |
AgeX Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 30, 2020
53.41 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,035
Rank
Percentile
Pharmaceuticals
Industry
of 806
Rank
Percentile
Pharmaceuticals
Subindustry
of 383
Rank
Percentile
AgeX Therapeutics FAQs
-
When was AgeX Therapeutics founded?
AgeX Therapeutics was founded in 2017.
-
Where is AgeX Therapeutics headquartered?
AgeX Therapeutics is headquartered in Alameda, CA.
-
What is the size of AgeX Therapeutics?
AgeX Therapeutics has 9 total employees.
-
What industry is AgeX Therapeutics in?
AgeX Therapeutics’s primary industry is Biotechnology.
-
Is AgeX Therapeutics a private or public company?
AgeX Therapeutics is a Private company.
-
What is AgeX Therapeutics’s current revenue?
The current revenue for AgeX Therapeutics is .
-
How much funding has AgeX Therapeutics raised over time?
AgeX Therapeutics has raised $10.8M.
-
Who are AgeX Therapeutics’s investors?
IBS Capital, James Mellon, Juvenescence, Kizoo Technology Capital, and National institutes of Neurological Disorders and Stroke have invested in AgeX Therapeutics.
-
Who are AgeX Therapeutics’s competitors?
Surrozen, CRISPR Therapeutics, Agenus, Sorrento Therapeutics, and Ember Therapeutics are some of the 55 competitors of AgeX Therapeutics.
-
When was AgeX Therapeutics acquired?
AgeX Therapeutics was acquired on 26-Mar-2024.
-
Who acquired AgeX Therapeutics?
AgeX Therapeutics was acquired by Serina Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
